Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellect Biotechnology Ltd. (also referenced as Quoin Pharmaceuticals, Ltd. in metadata) for the month of February 2017. The report, dated February 14, 2017, serves as a notification of a significant corporate action regarding the company's listing status.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate event rather than a financial statement.
Material Changes
On February 14, 2017, the Registrant announced its intention to file a petition with the Israeli court to voluntarily delist its ordinary shares from the Tel-Aviv Stock Exchange. This action is being taken in accordance with section 350 of the Israeli Companies Law.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future performance, or specific risk factors beyond the implications of the voluntary delisting. The document notes that this Form 6-K is incorporated by reference into the Company's Registration Statement on Form S-8 (Registration No. 333-214817).
Investor Verification Checklist
- Verify the status of the petition to delist from the Tel-Aviv Stock Exchange with the Israeli court.
- Confirm the impact of the delisting on the trading of ordinary shares and shareholder rights.
- Review the referenced Form S-8 (Registration No. 333-214817) for details on equity plans associated with this filing.
- Check for subsequent filings regarding the finalization of the delisting process.